U.S officials on Monday said the first human trial to evaluate a candidate vaccine against coronavirus disease 2019 has begun in Seattle.
The US National institutes of Health in a statement said “The open-label trial will enrol 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks,”.
“The first participant received the investigational vaccine today.”
